- BLUE has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $99.3 million.
- BLUE has traded 104,256 shares today.
- BLUE is down 3.1% today.
- BLUE was up 72.4% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in BLUE with the Ticky from Trade-Ideas. See the FREE profile for BLUE NOW at Trade-Ideas More details on BLUE: bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. Currently there are 5 analysts that rate bluebird bio a buy, no analysts rate it a sell, and none rate it a hold. The average volume for bluebird bio has been 405,400 shares per day over the past 30 days. Bluebird bio has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are up 133% year-to-date as of the close of trading on Monday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates bluebird bio as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow.